Last reviewed · How we verify
Parkinsonism
Approved treatments
- Inbrija · Merz
Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination. - pergolid · University Hospital Muenster
- Metixen · Novartis
- Sinemet Cr · Aton
Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms. - Norflex
- Artane
- Lodosyn · University of Miami
- Cogentin · University of Southern California
- Trivastal
Trivastal works by blocking the alpha-2C adrenergic receptor, which helps to increase dopamine levels in the brain. - Artane
- Kemadrine
- Akineton · AbbVie
- Gocovri · Endo
- Cogentin
- GOCOVRI · Oregon Health and Science University
- Amantadin · Centre Hospitalier Universitaire de Nice
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Parkinsonism patent landscape — cliff calendar, originator estates, attackable patents
- Parkinsonism treatment landscape brief
- Parkinsonism treatment updates RSS
Frequently asked questions about Parkinsonism
What drugs treat Parkinsonism?
Tracked treatments include Inbrija, pergolid, Metixen, Sinemet Cr, Norflex, Artane, Lodosyn, Cogentin.
What is the treatment for Parkinsonism?
Standard treatment for Parkinsonism includes Inbrija, pergolid, Metixen, Sinemet Cr, Norflex. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Parkinsonism patent cliff · Parkinsonism CI report
- Treatment: Inbrija · Merz
- Treatment: pergolid · University Hospital Muenster
- Treatment: Metixen · Novartis
- Treatment: Sinemet Cr · Aton
- Treatment: Norflex
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing